SCHEMBL16610753

SCHEMBL16610753

CC(C)[Si](c1ncc(-c2ncc(N3CCCC3c3ccc(F)cc3)nc2Cl)o1)(C(C)C)C(C)C

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.36
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 3/20 0.36
MEN1 O00255 2/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
PDE2A O00408 2/20 0.34
TDP1 Q9NUW8 1/20 0.33
NR3C2 P08235 1/20 0.33
RET P07949 1/20 0.33
JAK2 O60674 2/20 0.33
JAK3 P52333 1/20 0.33
NTRK1 P04629 3/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
TRPA1 O75762 1/20 0.31
CCNC P24863 1/20 0.30
CDK8 P49336 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16610789 0.80 RET (0.33) RETNTRK1CCNCCDK8
SCHEMBL16610951 0.74 NR3C2 (0.40) KDM4EKMT2AALDH1A1MEN1LMNA
SCHEMBL16610744 0.67 CYP19A1 (0.39) KMT2AMEN1PDE2AJAK2NTRK1
SCHEMBL16611213 0.65 CYP19A1 (0.37) KMT2AMEN1PDE2AJAK3HDAC8
SCHEMBL16754706 0.65 CYP19A1 (0.37) KMT2AMEN1PDE2AJAK3HDAC8
SCHEMBL16610738 0.64 KDM4E (0.37) KDM4EALDH1A1PDE2AHDAC8HDAC6
SCHEMBL20576681 0.63 JAK2 (0.53) LMNANR3C2RETJAK2JAK3
SCHEMBL28003806 0.63 PDE2A (0.35) KMT2AMEN1PDE2AJAK2JAK3
SCHEMBL28004260 0.63 ALDH1A1 (0.51) KDM4EKMT2AALDH1A1MAPTTDP1
SCHEMBL22327994 0.62 JAK2 (0.44) KDM4EKMT2AALDH1A1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170143722-A1 SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS NIPPON SHINYAKU CO., LTD. (JP) 2017-05-25 US disclosed
US-9580413-B2 Substituted pyrrolidines as ROS tyrosine kinase inhibitors NIPPON SHINYAKU CO., LTD. (JP) 2017-02-28 US disclosed
US-20150152095-A1 AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL NIPPON SHINYAKU CO., LTD. (JP) 2015-06-04 US disclosed
EP-2857398-A1 AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL Nippon Shinyaku Co., Ltd. (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152095-A1 AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL HRH4, CYP3A4, CYP3A5 KDM4E 1382/4885KMT2A 2423/4885ALDH1A1 1015/4885
US-20170143722-A1 SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS ROS1, NOX4, NOX3 KDM4E 1418/4885KMT2A 2202/4885ALDH1A1 1052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.